Product Images Rivaroxaban

This data appears to be from a clinical trial comparing the drug Rivaroxaban with a placebo. The information includes the number of subjects at risk over specific days from randomization, their cumulative incidence rate, and confidence intervals. The study involves 8313 subjects on Rivaroxaban and 8261 on placebo. Analysis of this data may provide insights into the effectiveness and safety of Rivaroxaban compared to a placebo in the given population.*

Population Description includes PK Fold Change and 90% Confidence Interval for categories such as End-Stage Renal Disease, Renal Impairment (Severe, Moderate, Mild), Age (75-83 years vs. 18-43 years), Body Weight (<=50 kg, 70-80 kg, 120 kg) and Hepatic Impairment (Moderate, Mild). The information provided pertains to differences in parameters such as AUC and Cmax, with references to creatinine clearance levels and a specific medication post hemodialysis for ESRD subjects.*

This text appears to be presenting data on the comparison between rivaroxaban and placebo in clinical trials, with details on outcomes based on age, sex, region, weight, renal function, medical history, surgery history, history of prior heart attack, baseline diabetes status, and baseline creatinine clearance. The results seem to show the efficacy and safety profiles favoring rivaroxaban over placebo based on the given parameters.*